Schizophrenic Symptom Change With Rehospitalization

1968 ◽  
Vol 19 (2) ◽  
pp. 227 ◽  
Author(s):  
Donald W. Morgan
1968 ◽  
Vol 13 (9) ◽  
pp. 492-493
Author(s):  
Loren J. Chapman

2012 ◽  
Author(s):  
Carmen Mclean ◽  
Edna Foa ◽  
Eliza Borah ◽  
Jim Mintz ◽  
Brad Evans ◽  
...  

2013 ◽  
Author(s):  
Ann C. Bilbrey ◽  
Aleksandra Stepanenko ◽  
Johanna Rengifo Nevarez ◽  
Renee Marquett ◽  
Dolores Gallagher-Thompson

1965 ◽  
Vol 1 (4) ◽  
pp. 310-318 ◽  
Author(s):  
Norbert Freedman ◽  
David Engelhardt ◽  
David Mann ◽  
Reuben Margolis ◽  
Sharon London

2021 ◽  
Vol 11 (8) ◽  
pp. 711
Author(s):  
Kara Dempster ◽  
Annie Li ◽  
Priyadharshini Sabesan ◽  
Ross Norman ◽  
Lena Palaniyappan

Although approximately 1/3 of individuals with schizophrenia are Treatment Resistant (TR), identifying these subjects prospectively remains challenging. The Treatment Response and Resistance in Psychosis working group defines <20% improvement as an indicator of TR, though its utility in First Episode Schizophrenia (FES) remains unknown. In a prospective cohort of FES (n = 129) followed up for 5 years, we evaluated two improvement thresholds for ‘probable TR’; <20% and <50% based on positive, negative, and total symptoms. We ascertained (1) the ecological validity (i.e., the ability to identify an expected subgroup of 1/3rd of patients); (2) the predictive validity (i.e., ability to predict poor global functioning) and (3) the clinical utility (association with clozapine use at the 5th year). Using the criteria of a total symptom reduction of <50% or negative symptom reduction of <20% resulted in ‘probable TR’ rates of 37% and 33%, respectively. Using <20% positive or total symptoms criteria resulted in very low rates, indicating minimal utility in FES. <50% total symptom criterion best predicted the global functioning over 5 years. Clozapine use was only predicted by positive symptom criterion. Prospective characterization of TRS is possible at 6 months after FES through a time-based approach using a 50% threshold for symptom change in treatment-adherent patients.


2021 ◽  
Vol 80 ◽  
pp. 102386
Author(s):  
J. Gayle Beck ◽  
Joshua D. Clapp ◽  
William Unger ◽  
Melissa Wattenberg ◽  
Denise M. Sloan

Author(s):  
Laurel D. Sarfan ◽  
Joshua C. Magee ◽  
Elise M. Clerkin

AbstractWidely-used, empirically-supported treatments focus on reducing experiential avoidance (EA) as a mechanism of social anxiety disorder (SAD) symptom change. However, little is known about how EA and SAD symptoms bidirectionally interrelate from session to session, or throughout the course of an intervention—a gap that raises significant theoretical and clinical questions about the mechanistic role of EA. Participants (N = 78) with elevated EA and SAD symptoms completed a 3-session pilot intervention (Approach-Avoidance Task training plus psychoeducation) designed to target EA. Bivariate latent change score modeling was then used to map the bidirectional, temporal interrelationships between EA and SAD symptoms from session to session. Analyses accounted for the overall trajectory of change in both variables (i.e., EA and SAD) and both variables’ preceding measurement. Findings suggested that changes in SAD symptoms preceded and predicted changes in EA from session to session. Contrary to hypotheses, this effect was not bidirectional, as changes in EA did not precede and predict changes in SAD symptoms from session to session. The use of a relatively small analogue sample limit the external validity of the present findings. Nevertheless, these novel findings advance our understanding of the dynamic interrelationships between EA and SAD symptoms throughout treatment. Moreover, given that many leading treatments target EA, this study highlights a need for future work to continue evaluating whether EA is indeed a mechanism of SAD symptom change.


Sign in / Sign up

Export Citation Format

Share Document